Patents by Inventor Marie-Alix Poul
Marie-Alix Poul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230183379Abstract: The invention relates to a bispecific antibody targeting TfR1 and a soluble antigen. The inventors demonstrate that the unique mode of interaction of the bispecific antibody with TfR1 increases its persistence in vivo through an FcRn-like mechanism. It has been demonstrated on MCF7 cell line that the bispecific antibody induces soluble antigen (IL6) uptake through TfR1 mediated endocytosis. Effects of the bispecific antibody on XG6 cell lines viability have been demonstrated, notably on iron and IL-6 deprivation. Hence, the inventors design an improved sweeping antibody which can specifically target tumors and inflammatory cells expressing TfR1. By its unique mode of interaction with TfR1, its ability to induce soluble uptake antigen through TfR1 mediated endocytosis and its capacity to deprive cells of iron, known for being required in tumors growth and progression and development of inflammatory pathologies, the bispecific antibody can be used in the treatment of cancer and inflammatory pathologies.Type: ApplicationFiled: November 20, 2019Publication date: June 15, 2023Inventors: Marie-Alix POUL, Adrien LAROCHE
-
Patent number: 10398774Abstract: The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.Type: GrantFiled: December 8, 2015Date of Patent: September 3, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIERInventors: Bruno Robert, Christel Larbouret, Pierre Martineau, Marie-Alix Poul
-
Patent number: 9932410Abstract: The invention relates to human neutralizing anti-KIT antibodies and uses thereof. More particularly, the invention relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.Type: GrantFiled: November 5, 2014Date of Patent: April 3, 2018Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier, Universite Paris- Sud, Institut Regional du Cancer du Montpellier, Ecole Normale Superieure de CachanInventors: Marie-Alix Poul, Mariane Le Gall, Ronan Crepin
-
Publication number: 20170340734Abstract: The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.Type: ApplicationFiled: December 8, 2015Publication date: November 30, 2017Inventors: Bruno ROBERT, Christel LARBOURET, Pierre MARTINEAU, Marie-Alix POUL
-
Publication number: 20160279262Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalizing into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: ApplicationFiled: June 9, 2016Publication date: September 29, 2016Inventors: James D. Marks, Marie Alix Poul
-
Publication number: 20160264680Abstract: The invention relates to human neutralizing anti-KIT antibodies and uses thereof. More particularly, the invention relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.Type: ApplicationFiled: November 5, 2014Publication date: September 15, 2016Inventors: Marie-Alix Poul, Mariane Le Gall, Ronan Crepin
-
Patent number: 9388244Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: February 20, 2015Date of Patent: July 12, 2016Assignee: The Regents of the University of CaliforniaInventors: James D. D. Marks, Marie Alix Poul
-
Publication number: 20150239976Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: ApplicationFiled: February 20, 2015Publication date: August 27, 2015Inventors: James D. D. Marks, Marie Alix Poul
-
Patent number: 8974792Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: April 6, 2012Date of Patent: March 10, 2015Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Publication number: 20130337039Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: ApplicationFiled: April 6, 2012Publication date: December 19, 2013Applicant: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Publication number: 20130045206Abstract: The present invention relates to a molecular structure characterised in that said structure includes at least one amino acid sequence selected from: SEQ. ID NO.: 1, SEQ. ID NO.: 2, SEQ. ID NO.: 3, SEQ. ID NO.: 4, SEQ. ID NO.: 5, SEQ. ID NO.: 6, SEQ. ID NO.: 7, SEQ. ID NO.: 8, SEQ. ID NO.: 9, SEQ. ID NO.: 10, SEQ. ID NO.: 11, SEQ. ID NO.: 12, SEQ. ID NO.: 13, SEQ. ID NO.: 14, SEQ. ID NO.: 15, SEQ. ID NO.: 16, SEQ. ID NO.: 17, SEQ. ID NO.: 18, SEQ. ID NO.: 19, SEQ. ID NO.: 20, SEQ. ID NO.: 21, SEQ. ID NO.: 22, SEQ. ID NO.: 23, SEQ. ID NO.: 24, SEQ. ID NO.: 25, SEQ. ID NO.: 26, SEQ. ID NO.: 27, SEQ. ID NO.: 28, SEQ. ID NO.: 29, SEQ. ID NO.: 30, SEQ. ID NO.: 31, SEQ. ID NO.: 32, SEQ. ID NO.: 33, SEQ. ID NO.: 34, SEQ. ID NO.: 35, SEQ. ID NO.: 36, said amino acid sequence corresponding to an antigen complementarity determining region (CDR) of the variable domain of the heavy chain (CDR-H) or the light chain (CDR-L) of an antibody targeting the human transferrin receptor (TfR).Type: ApplicationFiled: December 16, 2010Publication date: February 21, 2013Inventors: Marie-Alix Poul, Ronan Philippe Crepin, James D. Marks
-
Patent number: 8173424Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: December 16, 2010Date of Patent: May 8, 2012Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Publication number: 20110218333Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: ApplicationFiled: December 16, 2010Publication date: September 8, 2011Applicant: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Patent number: 7892554Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: June 1, 2007Date of Patent: February 22, 2011Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Publication number: 20090105086Abstract: This invention provides methods of selecting antibodies that are internalized into target cells. The methods generally involve contacting target cells with one or more members of an antibody phage display library. The members of the phage display library are also contacted with cells of a subtractive cell line. The target cells are then washed to remove the subtractive cell line cells and members of the phage display library that are non-specifically bound or weakly bound to the target cells. The target cells are cultured under conditions where members of the phage display library can be internalized if bound to an internalizing marker and internalized members of the phage display library are then identified.Type: ApplicationFiled: May 23, 2008Publication date: April 23, 2009Inventors: James D. Marks, Marie Alix Poul, Baltazar Becerril
-
Publication number: 20080108135Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: ApplicationFiled: June 1, 2007Publication date: May 8, 2008Applicant: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Patent number: 7244826Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: February 12, 1999Date of Patent: July 17, 2007Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Patent number: 6852507Abstract: Recombinant baculovirus used as an expression vector in the production of immunoglobulins with an insect cell. The invention is characterized by a first expression cassette comprising a first sequence coding for at least one portion of an immunoglobulin heavy chain, wherein the sequence is transcriptionally controlled by a first baculovirus promoter, and a second expression cassette comprising a second sequence coding for at least one portion of an immunoglobulin light chain, said second sequence being transcriptionally controlled by a second baculovirus promoter. The first and second promoters are two different promoters or derivatives of different promoters, the first and second promoters residing at different loci.Type: GrantFiled: November 21, 1997Date of Patent: February 8, 2005Assignees: Le Centre National de la Recherche ScientifiqueInventors: Martine Cerutti, Hassan Chaabihi, Gerard Devauchelle, Laurent Gauthier, Michel Kaczorek, Marie-Paule LeFranc, Marie-Alix Poul
-
Patent number: 6794128Abstract: This invention provides methods of selecting antibodies that are internalized into target cells. The methods generally involve contacting target cells with one or more members of an antibody phage display library. The members of the phage display library are also contacted with cells of a subtractive cell line. The target cells are then washed to remove the subtractive cell line cells and members of the phage display library that are non-specifically bound or weakly bound to the target cells. The target cells are cultured under conditions where members of the phage display library can be internalized if bound to an internalizing marker and internalized members of the phage display library are then identified.Type: GrantFiled: February 12, 1999Date of Patent: September 21, 2004Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul, Baltazar Becerril
-
Publication number: 20010008759Abstract: This invention provides methods of selecting antibodies that are internalized into target cells. The methods generally involve contacting target cells with one or more members of an antibody phage display library. The members of the phage display library are also contacted with cells of a subtractive cell line. The target cells are then washed to remove the subtractive cell line cells and members of the phage display library that are non-specifically bound or weakly bound to the target cells. The target cells are cultured under conditions where members of the phage display library can be internalized if bound to an internalizing marker and internalized members of the phage display library are then identified.Type: ApplicationFiled: February 12, 1999Publication date: July 19, 2001Inventors: JAMES D. MARKS, MARIE ALIX POUL, BALTAZAR BECERRIL